BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

930 related articles for article (PubMed ID: 30621125)

  • 1. Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy.
    Zahavi DJ; Weiner LM
    Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Checkpoint blockade after kidney transplantation.
    Lesouhaitier M; Dudreuilh C; Tamain M; Kanaan N; Bailly E; Legoupil D; Deltombe C; Perrin P; Manson G; Vigneau C; Houot R
    Eur J Cancer; 2018 Jun; 96():111-114. PubMed ID: 29705511
    [No Abstract]   [Full Text] [Related]  

  • 3. A decade of immune-checkpoint inhibitors in cancer therapy.
    Robert C
    Nat Commun; 2020 Jul; 11(1):3801. PubMed ID: 32732879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical autoimmune adverse effects with checkpoint blockade therapies.
    Friedman CF; Snyder A
    Ann Oncol; 2017 Feb; 28(2):206-207. PubMed ID: 27993802
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of immune checkpoint blockade for brain metastases.
    Harary M; Reardon DA; Iorgulescu JB
    CNS Oncol; 2019 Jun; 8(2):CNS33. PubMed ID: 30854898
    [No Abstract]   [Full Text] [Related]  

  • 6. [Not Available].
    Caux C; Bay JO
    Bull Cancer; 2018 Dec; 105 Suppl 1():S1-S2. PubMed ID: 30595190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?
    Rivera Vargas T; Apetoh L
    Front Immunol; 2019; 10():1181. PubMed ID: 31191545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in the clinical development of immune checkpoint blockade therapy.
    Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
    Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review.
    Moujaess E; Haddad FG; Eid R; Kourie HR
    Immunotherapy; 2019 Nov; 11(16):1409-1422. PubMed ID: 31621445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
    Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
    Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
    Hayashi H; Nakagawa K
    Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The next generation of immunotherapy: keeping lung cancer in check.
    Somasundaram A; Burns TF
    J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Masterful Antibodies: Checkpoint Blockade.
    Lonberg N; Korman AJ
    Cancer Immunol Res; 2017 Apr; 5(4):275-281. PubMed ID: 28373215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitors.
    Hui E
    J Cell Biol; 2019 Mar; 218(3):740-741. PubMed ID: 30760493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.
    Spain L; Larkin J
    Immunotherapy; 2016 Jun; 8(6):677-9. PubMed ID: 27197536
    [No Abstract]   [Full Text] [Related]  

  • 18. Mechanistic and pharmacologic insights on immune checkpoint inhibitors.
    Sweis RF; Luke JJ
    Pharmacol Res; 2017 Jun; 120():1-9. PubMed ID: 28323141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging role of checkpoint inhibition in localized bladder cancer.
    Singh P; Black P
    Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint blockade.
    Naidoo J; Page DB; Wolchok JD
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):585-600. PubMed ID: 24880949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.